查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1946629

2026年全球核子医学诊断市场报告

Nuclear Medicine Diagnostics Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，核医诊断市场发展迅速，预计将从2025年的78.8亿美元成长到2026年的88.4亿美元，复合年增长率达12.2%。过去几年的成长主要归功于放射性示踪剂在诊断中的应用日益广泛、医院核子医学科室的扩建、功能性影像需求的成长、Technetium放射性药物的广泛应用以及核子医学领域临床研究的进展。

预计未来几年核医诊断市场将快速成长，到2030年市场规模将达到137.7亿美元，复合年增长率（CAGR）为11.7%。预测期内的成长要素包括：对诊疗一体化（治疗诊断学）投资的增加、精准肿瘤诊断技术的日益普及、PET成像基础设施的扩展、对靶向放射性药物研发的日益重视以及对核诊断的监管支持力度加大。预测期内的主要趋势包括：基于PET的诊断放射性药物的日益普及、对个性化核诊断的需求不断增长、影像和治疗应用的融合程度不断提高、以肿瘤学为重点的核医学检测的扩展以及对短半衰期放射性示踪剂的日益关注。

预计未来几年，癌症发生率的不断上升将推动核医学诊断市场的扩张。癌症是指一组以异常细胞不受控制地生长和扩散为特征的疾病，这些异常细胞可在体内形成肿瘤。癌症发生率上升的主要原因是全球人口老化。癌症风险老龄化增长而显着增加，而医学进步也在延长寿命。核子医学诊断利用放射性物质，透过专用后续观察设备识别这些物质，从而产生器官结构和功能的详细影像，在多种癌症的检测、分期和追踪中发挥关键作用。例如，根据美国国家癌症研究所2025年5月发布的数据，2022年全球约有2,000万人被诊断出罹患癌症，导致970万人死亡。预计到2050年，每年新增病例将增加至3,300万例，癌症相关死亡人数将达1,820万人。因此，日益加重的癌症负担正在显着推动核医诊断市场的成长。

核子医学诊断市场的主要企业正致力于提供先进的医疗解决方案，以增强其竞争优势。先进的医疗技术指的是旨在帮助改善患者预后、提高护理标准和改善健康管理的创新工具和系统。例如，2023年8月，总部位于马来西亚的医疗服务供应商鹰阁医院宣布开设专门的核子医学科。该科室是一家配备最尖端科技并由训练有素的专业人员支持的专业医院，能够透过核子医学扫描术诊断技术实现疾病的早期发现、准确诊断和治疗。

目录

第一章执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球核子医学诊断市场：吸引力评分及分析
  • 成长潜力分析、竞争评估、策略契合度评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 主要原料、资源和供应商清单
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章 全球市场趋势与策略

  • 关键技术和未来趋势
    • 生物技术、基因组学和精准医学
    • 数位化、云端运算、巨量资料、网路安全
    • 工业4.0和智慧製造
    • 人工智慧（AI）和自主人工智慧
    • 永续性、气候技术和循环经济
  • 主要趋势
    • PET诊断放射性药物的应用日益增多
    • 对个人化核诊断的需求日益增长
    • 诊断影像与治疗应用融合方面的进展
    • 扩大核子医学检测范围，重点关注肿瘤学
    • 人们越来越关注短寿命放射性示踪剂

第五章 终端用户产业市场分析

  • 医院和诊断中心
  • 核子医学诊所
  • 研究所
  • 肿瘤中心
  • 学术医疗机构

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及新冠疫情对市场的影响

第七章 全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球核子医学诊断市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 全球核子医学诊断市场规模、比较及成长率分析
  • 全球核子医学诊断市场表现：规模与成长，2020-2025年
  • 全球核子医学诊断市场预测：规模与成长，2025-2030年，2035年预测

第八章 全球潜在市场规模（TAM）

第九章 市场细分

  • 按类型
  • SPECT放射性药物，PET放射性药物
  • 透过使用
  • 心臟病学、甲状腺病学、神经病学、肿瘤学及其他应用领域
  • 最终用户
  • 医院、诊断中心和研究机构
  • 按类型细分：SPECT放射性药物
  • 用于SPECT的Technetium-99m放射性药物、碘-123放射性药物、铊-201放射性药物和其他放射性药物
  • 按类型细分：PET放射性药物
  • 氟-18放射性药物、碳-11放射性药物、镓-68放射性药物和其他PET放射性药物

第十章 区域与国家分析

  • 全球核子医学诊断市场：依地区、绩效及预测划分，2020-2025年、2025-2030年预测、2035年预测
  • 全球核子医学诊断市场：依国家、绩效及预测划分，2020-2025年、2025-2030年预测、2035年预测

第十一章 亚太市场

第十二章：中国市场

第十三章 印度市场

第十四章 日本市场

第十五章：澳洲市场

第十六章 印尼市场

第十七章 韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第二十章：西欧市场

第21章英国市场

第22章 德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章 东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第30章：加拿大市场

第31章 南美洲市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第35章 市场监理与投资环境

第36章：竞争格局与公司概况

  • 核子医学诊断市场：竞争格局及市场占有率（2024年）
  • 核子医学诊断市场：公司估值矩阵
  • 核子医学诊断市场：公司概况
    • Siemens AG
    • Bayer Aktiengesellschaft
    • Novartis AG
    • GE Healthcare Technologies Inc.
    • Perkin Elmer Inc.

第37章：其他领先和创新企业

  • Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Eckert & Ziegler Strahlen-und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion（Canada）Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited

第38章 全球市场竞争基准分析与仪錶板

第39章 重大併购

第四十章：高潜力市场国家、细分市场与策略

  • 2030年核子医学诊断市场：提供新机会的国家
  • 2030年核子医学诊断市场：新兴细分市场机会
  • 2030年核子医学诊断市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第41章附录

简介目录
Product Code: ME4MNMDE01_G26Q1

Nuclear medicine employs radioactive substances administered internally to diagnose illnesses or selectively target and eliminate diseased or damaged organs and tissues during treatment. This field encompasses the utilization of radioactive drugs for research, therapeutic, and diagnostic objectives. In diagnostic nuclear medicine, radioactive tracers are employed to visualize and/or measure the overall or localized function of specific organs, providing valuable insights for medical diagnosis and treatment planning.

The primary categories of nuclear medicine diagnostics encompass SPECT radiopharmaceuticals and PET radiopharmaceuticals. SPECT Radiopharmaceuticals, or single-photon emission computerized tomography, pertain to gamma-ray tomographic imaging techniques employed in the field of nuclear medicine. These methods find application in diverse medical areas such as cardiology, thyroid, neurology, oncology, among others. End-users of these diagnostic technologies include hospitals, diagnostic centers, and research institutes.

Tariffs are impacting the nuclear medicine diagnostics market by increasing costs of imported radioisotopes, cyclotron components, imaging accessories, and specialized handling equipment. Diagnostic centers and hospitals in North America and Europe are most affected due to reliance on imported radiopharmaceutical inputs, while Asia-Pacific faces higher production and export costs. These tariffs are raising diagnostic procedure costs and affecting supply chain reliability. However, they are also encouraging domestic radioisotope production, regional supply chain strengthening, and investment in local radiopharmaceutical manufacturing capabilities.

The nuclear medicine diagnostics market research report is one of a series of new reports from The Business Research Company that provides nuclear medicine diagnostics market statistics, including nuclear medicine diagnostics industry global market size, regional shares, competitors with a nuclear medicine diagnostics market share, detailed nuclear medicine diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear medicine diagnostics industry. This nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $7.88 billion in 2025 to $8.84 billion in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to increasing use of radioactive tracers in diagnostics, expansion of hospital-based nuclear medicine units, rising demand for functional imaging, availability of technetium-based radiopharmaceuticals, growth of clinical research in nuclear medicine.

The nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $13.77 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to increasing investments in theranostics, rising adoption of precision oncology diagnostics, expansion of PET imaging infrastructure, growing focus on targeted radiopharmaceutical development, increasing regulatory support for nuclear diagnostics. Major trends in the forecast period include increasing adoption of pet-based diagnostic radiopharmaceuticals, rising demand for personalized nuclear diagnostics, growing integration of imaging and therapeutic applications, expansion of oncology-focused nuclear medicine procedures, enhanced focus on short-half-life radiotracers.

The growing incidence of cancer is anticipated to drive the expansion of the nuclear medicine diagnostics market in the coming years. Cancer refers to a group of diseases marked by the uncontrolled growth and spread of abnormal cells, which may form tumors within the body. The increasing prevalence of cancer is largely attributed to the aging global population, as cancer risk rises significantly with age, along with advances in healthcare that are extending life expectancy. Nuclear medicine diagnostics plays a critical role in the detection, staging, and monitoring of multiple cancer types by using radioactive substances that can be identified by specialized imaging systems to generate detailed images of organ structure and function. For example, in May 2025, data from the National Cancer Institute indicated that in 2022 nearly 20 million people worldwide were diagnosed with cancer and 9.7 million deaths were recorded, with projections estimating an increase to 33 million new cases and 18.2 million cancer-related deaths annually by 2050. As a result, the rising burden of cancer is contributing significantly to the growth of the nuclear medicine diagnostics market.

Leading companies operating in the nuclear medicine diagnostics market are increasingly focused on launching advanced medical solutions to strengthen their competitive positioning. Advanced medical technologies refer to innovative tools and systems designed to enhance patient outcomes, elevate standards of care, and support improved health management. For instance, in August 2023, Gleneagles Hospital, a Malaysia-based healthcare services provider, announced the launch of a dedicated Nuclear Medicine Unit. This unit is a specialized hospital facility equipped with state-of-the-art technology and supported by trained professionals, enabling early detection, accurate diagnosis, and treatment of diseases through nuclear medicine imaging techniques.

In March 2025, GE HealthCare Technologies, Inc., a United States-based medical technology and pharmaceutical company, acquired Nihon Medi Physics Co., Ltd. for an undisclosed consideration. Through this acquisition, GE HealthCare seeks to incorporate Nihon Medi Physics' strong capabilities in radiopharmaceutical development and manufacturing, thereby enhancing its ability to supply next-generation molecular imaging agents across neurology, cardiology, and oncology applications. Nihon Medi Physics Co., Ltd. is a Japan-based radiopharmaceutical company specializing in the development and supply of radioactive pharmaceuticals used in diagnostic nuclear medicine procedures.

Major companies operating in the nuclear medicine diagnostics market are Siemens AG, Bayer Aktiengesellschaft, Novartis AG, GE Healthcare Technologies Inc., Perkin Elmer Inc., Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited, Actinium Pharmaceuticals Inc., Jubilant DraxImage Inc., PharmaLogic Holdings Corp, Institute of Isotopes Co Ltd., Theragnostics Ltd., EczacIbasI-Monrol Nuclear Products Co.

North America was the largest region in the nuclear medicine diagnostics market in 2025. The regions covered in the nuclear medicine diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The nuclear medicine diagnostics market consists of sales of renal scan, bone scan, gallium scan, heart scan, brain scan and breast scan diagnostics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nuclear Medicine Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nuclear medicine diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nuclear medicine diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: SPECT Radiopharmaceuticals; PET Radiopharmaceuticals
  • 2) By Application: Cardiology; Thyroid; Neurology; Oncology; Other Applications
  • 3) By End-User: Hospitals And Diagnostic Centers; Research Institutes
  • Subsegments:
  • 1) By SPECT Radiopharmaceuticals: Technetium-99m-Based Radiopharmaceuticals; Iodine-123-Based Radiopharmaceuticals; Thallium-201-Based Radiopharmaceuticals; Other SPECT Radiopharmaceuticals
  • 2) By PET Radiopharmaceuticals: Fluorine-18-Based Radiopharmaceuticals; Carbon-11-Based Radiopharmaceuticals; Gallium-68-Based Radiopharmaceuticals; Other PET Radiopharmaceuticals
  • Companies Mentioned: Siemens AG; Bayer Aktiengesellschaft; Novartis AG; GE Healthcare Technologies Inc.; Perkin Elmer Inc.; Mallinckrodt Pharmaceuticals; Bracco Diagnostics Inc.; Lantheus Holdings Inc.; IBA Radiopharma Solutions; Curium SAS; Eckert & Ziegler Strahlen- und Medizintechnik AG; Advanced Accelerator Applications; Telix Pharmaceuticals Limited; Nordion (Canada) Inc.; NorthStar Medical Technologies LLC; SHINE Medical Technologies LLC; Navidea Biopharmaceuticals Inc.; Cyclopharm Limited; Isologic Innovative Radiopharmaceuticals; Clarity Pharmaceuticals Limited; Actinium Pharmaceuticals Inc.; Jubilant DraxImage Inc.; PharmaLogic Holdings Corp; Institute of Isotopes Co Ltd.; Theragnostics Ltd.; EczacIbasI-Monrol Nuclear Products Co.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Nuclear Medicine Diagnostics Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Nuclear Medicine Diagnostics Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Nuclear Medicine Diagnostics Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Nuclear Medicine Diagnostics Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Sustainability, Climate Tech & Circular Economy
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Pet-Based Diagnostic Radiopharmaceuticals
    • 4.2.2 Rising Demand For Personalized Nuclear Diagnostics
    • 4.2.3 Growing Integration Of Imaging And Therapeutic Applications
    • 4.2.4 Expansion Of Oncology-Focused Nuclear Medicine Procedures
    • 4.2.5 Enhanced Focus On Short-Half-Life Radiotracers

5. Nuclear Medicine Diagnostics Market Analysis Of End Use Industries

  • 5.1 Hospitals And Diagnostic Centers
  • 5.2 Nuclear Medicine Clinics
  • 5.3 Research Institutes
  • 5.4 Oncology Centers
  • 5.5 Academic Medical Institutions

6. Nuclear Medicine Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Nuclear Medicine Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Nuclear Medicine Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Nuclear Medicine Diagnostics Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Nuclear Medicine Diagnostics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Nuclear Medicine Diagnostics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Nuclear Medicine Diagnostics Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Nuclear Medicine Diagnostics Market Segmentation

  • 9.1. Global Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • SPECT Radiopharmaceuticals, PET Radiopharmaceuticals
  • 9.2. Global Nuclear Medicine Diagnostics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cardiology, Thyroid, Neurology, Oncology, Other Applications
  • 9.3. Global Nuclear Medicine Diagnostics Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals And Diagnostic Centers, Research Institutes
  • 9.4. Global Nuclear Medicine Diagnostics Market, Sub-Segmentation Of SPECT Radiopharmaceuticals, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Technetium-99m-Based Radiopharmaceuticals, Iodine-123-Based Radiopharmaceuticals, Thallium-201-Based Radiopharmaceuticals, Other SPECT Radiopharmaceuticals
  • 9.5. Global Nuclear Medicine Diagnostics Market, Sub-Segmentation Of PET Radiopharmaceuticals, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Fluorine-18-Based Radiopharmaceuticals, Carbon-11-Based Radiopharmaceuticals, Gallium-68-Based Radiopharmaceuticals, Other PET Radiopharmaceuticals

10. Nuclear Medicine Diagnostics Market Regional And Country Analysis

  • 10.1. Global Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Nuclear Medicine Diagnostics Market

  • 11.1. Asia-Pacific Nuclear Medicine Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Nuclear Medicine Diagnostics Market

  • 12.1. China Nuclear Medicine Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Nuclear Medicine Diagnostics Market

  • 13.1. India Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Nuclear Medicine Diagnostics Market

  • 14.1. Japan Nuclear Medicine Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Nuclear Medicine Diagnostics Market

  • 15.1. Australia Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Nuclear Medicine Diagnostics Market

  • 16.1. Indonesia Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Nuclear Medicine Diagnostics Market

  • 17.1. South Korea Nuclear Medicine Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Nuclear Medicine Diagnostics Market

  • 18.1. Taiwan Nuclear Medicine Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Nuclear Medicine Diagnostics Market

  • 19.1. South East Asia Nuclear Medicine Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Nuclear Medicine Diagnostics Market

  • 20.1. Western Europe Nuclear Medicine Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Nuclear Medicine Diagnostics Market

  • 21.1. UK Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Nuclear Medicine Diagnostics Market

  • 22.1. Germany Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Nuclear Medicine Diagnostics Market

  • 23.1. France Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Nuclear Medicine Diagnostics Market

  • 24.1. Italy Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Nuclear Medicine Diagnostics Market

  • 25.1. Spain Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Nuclear Medicine Diagnostics Market

  • 26.1. Eastern Europe Nuclear Medicine Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Nuclear Medicine Diagnostics Market

  • 27.1. Russia Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Nuclear Medicine Diagnostics Market

  • 28.1. North America Nuclear Medicine Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Nuclear Medicine Diagnostics Market

  • 29.1. USA Nuclear Medicine Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Nuclear Medicine Diagnostics Market

  • 30.1. Canada Nuclear Medicine Diagnostics Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Nuclear Medicine Diagnostics Market

  • 31.1. South America Nuclear Medicine Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Nuclear Medicine Diagnostics Market

  • 32.1. Brazil Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Nuclear Medicine Diagnostics Market

  • 33.1. Middle East Nuclear Medicine Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Nuclear Medicine Diagnostics Market

  • 34.1. Africa Nuclear Medicine Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Nuclear Medicine Diagnostics Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Nuclear Medicine Diagnostics Market Regulatory and Investment Landscape

36. Nuclear Medicine Diagnostics Market Competitive Landscape And Company Profiles

  • 36.1. Nuclear Medicine Diagnostics Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Nuclear Medicine Diagnostics Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Nuclear Medicine Diagnostics Market Company Profiles
    • 36.3.1. Siemens AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. GE Healthcare Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Perkin Elmer Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Nuclear Medicine Diagnostics Market Other Major And Innovative Companies

  • Mallinckrodt Pharmaceuticals, Bracco Diagnostics Inc., Lantheus Holdings Inc., IBA Radiopharma Solutions, Curium SAS, Eckert & Ziegler Strahlen- und Medizintechnik AG, Advanced Accelerator Applications, Telix Pharmaceuticals Limited, Nordion (Canada) Inc., NorthStar Medical Technologies LLC, SHINE Medical Technologies LLC, Navidea Biopharmaceuticals Inc., Cyclopharm Limited, Isologic Innovative Radiopharmaceuticals, Clarity Pharmaceuticals Limited

38. Global Nuclear Medicine Diagnostics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Nuclear Medicine Diagnostics Market

40. Nuclear Medicine Diagnostics Market High Potential Countries, Segments and Strategies

  • 40.1 Nuclear Medicine Diagnostics Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Nuclear Medicine Diagnostics Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Nuclear Medicine Diagnostics Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer